Acted like it's already bigger: a recent, in-motion company decision that only makes sense if the step-up is real
The model's full reasoning — Q3 2023 call → NOWe need answer YES or NO. Need analyze transcript. Question: Does management describe at least one specific decision company itself recently made and already acting on within last quarter or two that visibly enlarges what company set up to do, AND explain by pointing to demand/business already real? We need use only transcript. Let's parse. Company COMPASS Pathways, Phase III trials in TRD. They mention site initiations, expanding sites, adding sites for anorexia (2 additional clinical sites in Ireland and Texas, phone-based screening, reduced visits). But is that enlarging? It's clinical trial expansion. Need see if decision recent and already acting on, and reason demand real. Also pre-commercial work, investing in infrastructure? They mention "We also continue to invest in our pre-commercial work to ensure we're prepared for a successful COMP 360 launch, if approved" - generic, future. They mention August financing extended runway. Not enlargement. They mention "we have taken some steps, including adding 2 additional clinical sites in Ireland and Texas, phone-based screening, reduced numbers of in-person visits and other protocol amendments to reduce the burden on the patient." This is for anorexia study. Is that enlarging? Adding sites is capacity. But reason? They say anorexia nervosa is challenging, patients don't recognize need, high mortality, no FDA-approved treatments. They are not ready to update guidance on completion. They added sites to reduce burden. Is that demand already real? Not really; it's to address recruitment challenges, not demand. Also it's clinical trial, not commercial. What about Phase III site initiations: "3/4 of COMP005 sites have been initiated. And 006, we now have approval for sites in the U.S., Canada, U.K. and a number of EU countries. Patient demand is strong, given the degree of unmet need in this population." They are opening sites. Is that a recent decision? They are continuing to advance. But is it enlarging? They are initiating sites for trials. The decision to open sites is part of ongoing trial, not necessarily a new enlargement. They mention complexities can impact early recruitment, but patient demand strong. However, is this a specific decision recently made? They are "implementing all steps to ensure we remain on track." Not specific. Also external environment: Spravato sales growth, infrastructure.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| CHT | Chunghwa Telecom Co., Ltd. | Q4 2023 | 2024-01-30 | C |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| GRBK | Green Brick Partners, Inc. | Q3 2023 | 2023-11-01 | B |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| FSBC | Five Star Bancorp | Q3 2023 | 2023-10-31 | B |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| ET | Energy Transfer LP | Q2 2023 | 2023-08-02 | C+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| TSN | Tyson Foods, Inc. | Q2 2023 | 2023-05-08 | D |
| THS | TreeHouse Foods, Inc. | Q1 2023 | 2023-05-08 | B+ |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| TGT | Target Corporation | Q4 2022 | 2023-02-28 | C |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| WGO | Winnebago Industries, Inc. | Q1 2023 | 2022-12-16 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| CIG | Companhia Energética de Minas Gerais | Q3 2022 | 2022-11-16 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| TWO | Two Harbors Investment Corp. | Q2 2022 | 2022-08-04 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| ZENV | Zenvia Inc. | Q4 2021 | 2022-03-17 | C+ |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| FORM | FormFactor, Inc. | Q4 2021 | 2022-02-02 | B |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| LMAT | LeMaitre Vascular, Inc. | Q3 2021 | 2021-10-29 | C+ |
| MD | Pediatrix Medical Group, Inc. | Q3 2021 | 2021-10-28 | B |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| GNK | Genco Shipping & Trading Limited | Q2 2021 | 2021-08-07 | A |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| AX | Axos Financial, Inc. | Q4 2021 | 2021-07-29 | C+ |
| JPM | JPMorgan Chase & Co. | Q2 2021 | 2021-07-13 | A |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| ALKS | Alkermes plc | Q3 2018 | 2018-10-23 | C |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| NOVT | Novanta Inc. | Q4 2017 | 2018-05-12 | B+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| IR | Ingersoll-Rand Plc | Q3 2017 | 2017-10-25 | B |
| SBFG | SB Financial Group, Inc. | Q3 2017 | 2017-10-20 | A |
| STKL | SunOpta Inc. | Q2 2017 | 2017-08-09 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| PPG | PPG Industries, Inc. | Q1 2017 | 2017-04-20 | C |
| ATO | Atmos Energy Corporation | Q1 2017 | 2017-02-08 | A |
| THRM | Gentherm Incorporated | Q2 2016 | 2016-07-28 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
| ENLC | EnLink Midstream, LLC | Q4 2015 | 2016-02-17 | C+ |
| SON | Sonoco Products Company | Q4 2015 | 2016-02-11 | B |
JBHT · Q2 2022 → YESThe question is about whether management describes a specific recent decision the company made and is acting on that enlarges what they can do, justified by real existing demand, not hoped-for. YES In the transcript, management describes a concrete recent decision to expand capacity in multiple segments, already in motion and justified by real, current demand rather than forecasts. For Dedicated: "After selling 600 trucks in Q1, we sold slightly over 800 trucks in the second quarter... We've added nearly 2, 200 trucks to our business in the last 12 months... This unprecedented demand and growth for our highly engineered Fleet Service has put a strain on the organization, and the team has responded extremely well to the challenge." They are actively onboarding new business with strong backlog and pipeline, and will hold trades on roughly 4,000 tractors this year to support replacement and growth. For Intermodal: "Demand for our capacity continues to be greater than our ability to serve that demand... volumes by month for the quarter were up 4% in April, up 9% in May and up 10% in June on a year-over-year basis.
PRPO · Q3 2018 → YESThe question is: Does management describe at least one SPECIFIC DECISION THE COMPANY ITSELF RECENTLY MADE AND IS ALREADY ACTING ON — within roughly the last quarter or two — that visibly ENLARGES what...YES The transcript shows management describing a concrete, recent decision to expand the sales force by hiring top-notch individuals in Q3, resulting in a 10-member team that contributed to pathology services revenue growth of nearly 50% from the prior quarter. This is tied directly to real business activity: the sales team’s traction in securing new customers and converting pipeline, with management noting the growth is already occurring and expecting continued acceleration. Separately, they describe launching HemeScreen externally after internal validation, citing immediate real demand through numerous orders received from physicians just weeks after launch, which enlarges their offering and is presented as a meaningful step toward capturing 2019 revenue. Both examples meet the criteria as specific, already-in-motion enlargements justified by current, visible business rather than forecasts.
LOPE · Q2 2021 → YESThe question is about whether management describes a specific recent decision that enlarges the company's capabilities, based on real existing demand. YES Management describes GCE’s recent, concrete decision to expand its Orbis platform by signing contracts for new partners in Southern California and New York City markets and opening medical lab science programs with two additional partners. This enlarges the company’s off-campus classroom and laboratory capacity (currently 31 sites, targeting 40 by 2022). The decision is already in motion: one new site opened in spring 2021, two more in summer 2021, and further openings are scheduled for fall 2021 and 2022. Management ties this directly to real, already-arriving business—specifically, the 13.2% year 2021 enrollment growth at Orbis sites (up 19% in nursing) and the fact that partner institutions are actively seeking additional revenue streams because they derive 14% of revenues from GCE/Orbis programs and want to do more.